Loading…
Lunai Bioworks Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in LNAI.
▼ -99.7% over 5Y.
today you would have $3.58▼ -99.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $7.06 | $66.88 | $253.60 | $82.40 | |
| P/B | 1.0x | — | 1.0x | 4.3x | 0.8x |
| EPS | -$86.40 | -$72.80 | -$56.80 | -$172.80 | |
| ROE | -85.34% | — | -67.00% | -85.34% | -156.20% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AZTRAzitra, Inc. | $0.18 | 8.8x | 1.5x | — | -256.67% | $10.72M |
| GDTCCytoMed Therapeutics Ltd | $0.92 | — | 2.1x | — | -50.28% | $10.89M |
| APREAprea Therapeutics, Inc. | $0.84 | — | 0.3x | — | -46.15% | $10.56M |
| MTVAMetaVia Inc. | $1.70 |
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Company description provided by Yahoo Finance.
| — |
| 1.6x |
| — |
| -175.68% |
| $11.2M |
| VTGNVistagen Therapeutics, Inc. | $0.25 | — | 0.5x | — | -166.46% | $11.22M |
| TOVXTheriva Biologics, Inc. | $0.25 | 0.2x | 0.9x | — | -101.87% | $11.25M |